2017 Preview: Fresh Concerns And New Hopes In China
If 2016's Year of the Monkey was a period of ups and downs in China, filled with a series of rapid changes in regulations and plans for overseas expansion by domestic pharma companies, 2017's Year of the Rooster is likely to be even more uncertain, industry insiders say.
You may also be interested in...
Manufacturers beware, the rollout of a new receipts system could impact how drugs are distributed and sold to public hospitals in China over the course of the new year.
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
The world’s second-largest economy is fast moving away from reforms and open to a "dual circulation" model, focusing on domestic market consumption while reducing export-driven production. Executives and investors shared views at a conference on whether multinational pharma firms are still welcome in China and what opportunities may lie in the drastic policy shift.